Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Impact · against what's priced in

The ESMO pipeline updates provide incremental positive catalysts for Eli Lilly by adding value to the next-generation oncology pipeline, which the market currently does not price in. While the GLP-1 segment remains the primary price driver, these advances in ADC and KRAS therapies offer diversification and growth potential beyond the current 30% revenue CAGR assumption.

LLY+0.30

Challenges what's priced in

The price assumes